Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 10, 2004. The report details changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs) resulting from employee incentive plans and retirement fund movements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details and does not contain consolidated financial statements or performance metrics.
Material Changes
Material changes reported relate to specific share transactions within employee benefit schemes:
- GSK Trust Transactions: On September 8, 2004, the GSK Trust transferred 1,128 Ordinary Shares to a participant in the SmithKline Beecham Mid Term Incentive Plan and sold 784 Ordinary Shares on behalf of a participant at GBP 11.41099 per share.
- US Retirement Savings Plan: On September 9, 2004, the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan decreased from 19,172,434 to 19,146,649 due to fund movements, at an average price of $41.58.
- Director Share Acquisition: On September 9, 2004, Director Mr. J D Coombe acquired 22 Ordinary Shares (11 via personal contribution and 11 via company matching) under the ShareReward Plan at GBP 11.50 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share interests and does not include forward-looking statements or risk assessments.
Investor Verification Checklist
- Verify the impact of the reported share sales and transfers on the total outstanding share count.
- Confirm the current market price of GSK Ordinary Shares and ADRs relative to the transaction prices cited (GBP 11.41, GBP 11.50, and $41.58).
- Review the full terms of the SmithKline Beecham Mid Term Incentive Plan and the ShareReward Plan to understand vesting schedules and future dilution potential.
- Check subsequent filings for any further changes in director interests or significant corporate actions.